Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results | Global News Avenue

Novo NordNon -governmental organization) On Friday morning, after the early results of this Danish pharmaceutical dealer announced the early results of its ectumin diet pills, the stock price of the United States soared by 9%.

Ozempic and wegovy manufacturers said that its 1B/2A stage Clinical trial Studies have shown that under the three different maintenance doses, people’s average baseline weight decreases from 92.7 kg (202.8 pounds), but the human body weight received by placebo treatment has increased. Under the highest dose of 20 mg, the participants’ weight decreased by 22%after 36 weeks, while the human body weight received by placebo was increased by 2%.

When taking a dose of 1.25 mg within 20 weeks, patients receiving germillin were alleviated by 9.7%, while patients taking placeboat increased by 1.9%. Within 28 weeks, the body weight of 5 mg of doses dropped by 16.2%, while the human body weight of the placebo was increased by 2.3%.

Martin Lange, executive vice president responsible for development, said Novo was “very encouraged” about the result. The company said that it is currently planned to “further carry out the clinical development of pancreatic enzymes in an overweight or obese adults.”

Novo Nord’s stock has been lower after the performance is disappointing

Novo’s stock price in the United States has been in a downward trend Since SeptemberPlummeted 18% One day last month The test results of its weight loss pill Cagrisema are disappointing.

Novo Nordisk’s stock, the company is the leader of the field Weight loss market Cooperate with Mounjaro and Zepbound manufacturer Eli Lilly (Benefit), About 23%of the past 12 months as of Friday. The stock price of Lili Lili fell 1%shortly after the market, but rose about 20%from last year.